TrialMultiple sclerosis (Houndmills, Basingstoke, England)2018

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.

Stanley Cohan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.